EIF2AK4 and pulmonary hypertension: Conversely, in preclinical models of pulmonary hypertension, pharmacological activation of GCN2 by halofuginone has been shown to attenuate vascular remodeling, oxidative stress, and inflammation—supporting a protective role in this pathological setting [94,126,127].